Biden officials unveil pandemic defense measures while Trump plans potential rollbacks highlight contrasting health strategies ahead of the transition.
Moderna forecasts a substantial revenue dip for 2025, causing share prices to plunge while the firm accelerates cost-cutting efforts amidst dwindling vaccine demand.